Access cutting-edge fibrodysplasia ossificans progressiva treatment through this clinical trial at a research site in San Francisco. Study-provided care at no cost to qualified participants.
Quick Self-Assessment
See if you qualify for this San Francisco location
Preparing your pre-screening questions…
Access fibrodysplasia ossificans progressiva specialists at no cost
This study follows strict safety protocols and ethical guidelines
All study-related fibrodysplasia ossificans progressiva treatment provided free
Check if you qualify for this fibrodysplasia ossificans progressiva clinical trial in San Francisco, CA
No-Cost Study Care
Local to San Francisco
Convenient for CA residents
Cutting-Edge Treatment
Access to innovative therapies
Expert Medical Care
Close monitoring by specialists
Possible Compensation*
For time and travel
*Compensation varies by study. Confirm details with coordinator.
The participants in this registry study will have fibrodysplasia ossificans progressiva (FOP). FOP is an ultra-rare, severely disabling disease characterized by new bone formation in areas of the body where bone is not normally present (heterotopic ossification (HO)). HO is often preceded by painful, recurrent episodes of soft tissue swelling (flare-ups). This registry study will take place in countries where the treatment, known as palovarotene, has been approved for use. Participants will either be treated with palovarotene (i.e already be receiving palovarotene as prescribed by their treating physician according to locally approved product information) or untreated with palovarotene. The main aim of this registry study will be to collect and assess real-world safety data on children and adult participants with FOP treated with palovarotene. This registry study will also describe the effectiveness of palovarotene in exposed participants, including the effect on everyday activities and physical performance. In addition, this registry study aims to descriptively compare key safety outcomes (i.e. flare-up episodes, growth outcomes, and bone fractures) between participants exposed and unexposed to palovarotene.
Sponsor: Ipsen
Yes, this clinical trial (NCT06089616) has an active research site in San Francisco, CA that is currently enrolling participants.
Clinical trials follow strict safety guidelines and ethical standards. This study has been reviewed and approved, and participants are closely monitored by medical professionals. You can withdraw at any time.
Many clinical trials offer compensation for your time and travel expenses. Specific compensation details will be discussed during the screening process. All study-related medical care is provided at no cost.
Absolutely. Participation is completely voluntary. You have the right to withdraw from the study at any time, for any reason, without penalty.
If you're searching for fibrodysplasia ossificans progressiva treatment options in San Francisco, CA, this clinical trial (NCT06089616) may be an excellent opportunity. Clinical trials provide access to cutting-edge treatments that aren't yet available to the general public, often at no cost to participants.
Our San Francisco research site is actively enrolling participants for this clinical trial. You'll receive care from experienced fibrodysplasia ossificans progressiva specialists who are at the forefront of medical research. All study-related care, including examinations, treatments, and monitoring, is provided at no cost to qualified participants.
Looking for more options? Browse all fibrodysplasia ossificans progressiva clinical trials near you to find additional studies recruiting in your area.
See all ankylosing spondylitis clinical trials recruiting in San Francisco — not just this study.
Browse Ankylosing Spondylitis Trials in San Francisco →